141 related articles for article (PubMed ID: 20443001)
1. Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers.
Sugimoto H; Iwamoto T; Murashima Y; Tabata T; Sagawa N; Okuda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):415-9. PubMed ID: 20443001
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer.
Gadducci A; Tana R; Teti G; Zanca G; Fanucchi A; Genazzani AR
Int J Gynecol Cancer; 2008; 18(4):615-20. PubMed ID: 18754135
[TBL] [Abstract][Full Text] [Related]
3. Weekly dosing of carboplatin increases risk of allergy in children.
Yu DY; Dahl GV; Shames RS; Fisher PG
J Pediatr Hematol Oncol; 2001; 23(6):349-52. PubMed ID: 11563768
[TBL] [Abstract][Full Text] [Related]
4. Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions.
Kawarada Y; Miyazaki M; Itoh A; Araki R; Iwamizu H; Kataoka T; Kumakura Y; Ota A; Nagai T; Yamada K
Int J Clin Oncol; 2017 Jun; 22(3):593-599. PubMed ID: 28124284
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin hypersensitivity induced by low-dose paclitaxel/carboplatin in multiple platinum-treated patients with recurrent ovarian cancer.
Watanabe Y; Nakai H; Ueda H; Nozaki K; Hoshiai H
Int J Gynecol Cancer; 2005; 15(2):224-7. PubMed ID: 15823103
[TBL] [Abstract][Full Text] [Related]
6. [Safety and Efficacy of Cisplatin Treatment after Carboplatin Hypersensitivity Reactions in Gynecologic Malignancies].
Matsuoka N; Yokoyama T; Fujimoto E; Sakai M; Okame S; Shiroyama Y; Yokoyama T; Takehara K
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2091-2095. PubMed ID: 29361624
[TBL] [Abstract][Full Text] [Related]
7. Drug fever induced by carboplatin-based regimens: Higher incidence in a women's hospital.
Zhang X; Zhao M; Zheng C
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):882-887. PubMed ID: 34507666
[TBL] [Abstract][Full Text] [Related]
8. Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
Schwartz JR; Bandera C; Bradley A; Brard L; Legare R; Granai CO; Dizon DS
Gynecol Oncol; 2007 Apr; 105(1):81-3. PubMed ID: 17157366
[TBL] [Abstract][Full Text] [Related]
9. Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin.
Arimoto T; Oda K; Nakagawa S; Kawana K; Tsukazaki T; Adachi K; Matsumoto Y; Yano T; Kozuma S; Taketani Y
J Obstet Gynaecol Res; 2013 Jan; 39(1):336-40. PubMed ID: 22690725
[TBL] [Abstract][Full Text] [Related]
10. Effect of Prophylactic Extended-Infusion Carboplatin on Incidence of Hypersensitivity Reactions in Patients with Ovarian, Fallopian Tube, or Peritoneal Carcinomas.
Pasternak AL; Link NA; Richardson CM; Rose PG
Pharmacotherapy; 2016 Jul; 36(7):723-30. PubMed ID: 27196693
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
[TBL] [Abstract][Full Text] [Related]
12. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Jerzak KJ; Deghan Manshadi S; Ng P; Maganti M; McCuaig JM; Bulter M; Oza A; Mackay HJ
J Oncol Pharm Pract; 2018 Mar; 24(2):83-90. PubMed ID: 27856924
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.
Kolomeyevskaya NV; Lele SB; Miller A; Riebandt GC; Blum BL; Odunsi KO; Frederick PJ
Int J Gynecol Cancer; 2015 Jan; 25(1):42-8. PubMed ID: 25356535
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Carboplatin-related hypersensitivity reactions in Japanese patients with gynecologic malignancies.
Koshiba H; Hosokawa K; Kubo A; Miyagi Y; Oda T; Miyagi Y; Watanabe A; Honjo H
Int J Gynecol Cancer; 2009 Apr; 19(3):460-5. PubMed ID: 19407575
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status.
Rolfe M; Gegeckas C; Turner S; Orr JW
J Oncol Pharm Pract; 2021 Oct; 27(7):1704-1709. PubMed ID: 33100178
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis.
Hayashi T; Shimokawa M; Matsuo K; Iihara H; Kawada K; Nakano T; Egawa T
BMC Cancer; 2021 Jan; 21(1):74. PubMed ID: 33451299
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies.
Michikami H; Minaguchi T; Ochi H; Onuki M; Okada S; Matsumoto K; Satoh T; Oki A; Yoshikawa H
J Obstet Gynaecol Res; 2013 Jan; 39(1):330-5. PubMed ID: 22640034
[TBL] [Abstract][Full Text] [Related]
19. [Clinical analysis of thirteen cases of hypersensitivity reactions to carboplatin.].
Wang HB; Shen K; Yang JX; Huang HF; Li Y; Wu M; Pan LY
Zhonghua Fu Chan Ke Za Zhi; 2009 Nov; 44(11):837-40. PubMed ID: 20079036
[TBL] [Abstract][Full Text] [Related]
20. Clinical features of hypersensitivity reactions to carboplatin.
Markman M; Kennedy A; Webster K; Elson P; Peterson G; Kulp B; Belinson J
J Clin Oncol; 1999 Apr; 17(4):1141. PubMed ID: 10561172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
